Immunological
The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.
Deal Snapshot: The French drugmaker gains rights to the anti-CD19xBCMAxCD3 candidate, which is designed to have the benign safety profile considered especially important in immunology.
With Phase III plans underway and Part B data from its APEX trial due in 2026, Apogee is banking on zumilokibart's extended dosing advantage compared with rivals.
Phase II results evaluating the anti-TSLP drug bosakitug are expected in the fourth quarter. Aclaris is pitching the asset as having best-in-class potential in a currently open field.
The drug is the first oral IL-23 receptor antagonist to clear the US FDA. Johnson & Johnson and partner Protagonist Therapeutics are banking on its convenience as well as efficacy and safety to make the drug competitive.
The biotech believes its Treg, QEL-005, can surpass existing therapies by modulating a range of pro-inflammatory mechanisms in complex immune conditions.
As the Belgian firm's blockbuster beats AbbVie's Skyrizi in a head-to-head psoriatic arthritis study.
Povetacicept’s Phase III results strengthen Vertex’s push to expand beyond cystic fibrosis, with the company expected to complete the drug’s rolling submission by the end of March.
The company is advancing tilrekimig into Phase III development based on positive Phase II efficacy data that suggest a potential improvement over biologic standard of care Dupixent.
Qilu’s bifunctional combo of PD-1 and CTLA-4 antibodies hits its marks in a Phase III cervical cancer trial, while Lynk’s JAK1 inhibitor logs similar win in atopic dermatitis.
Sanofi gets its new CEO next month, and Belén Garijo will be confronted with hard choices on how to improve the firm's hit and miss R&D record.
Hansa Biopharma was not awarded a priority review for imlifidase but analysts nevertheless predict an ‘inflection point’ for the Swedish company.
AbbVie chief scientific officer Thakkar talked about ways to avoid pitfalls in immunology studies, while Neurocrine chief scientific officer Onyia outlined the company’s new obesity strategy, among other updates.
UCB is paying $1bn-plus for global rights to Antengene's ATG-201, an anti-CD19/CD3 T-cell engager, as it looks to build its strength in immunology.
Deal Snapshot: By paying Sino Biopharm up to $1.5bn, Sanofi appears to planning for its new Chinese partner’s JAK/ROCK inhibitor rovadicitinib to pick up where its own Rezurock left off in first-line, chronic graft-versus-host disease.
The US FDA gave priority review to the JAK1/TYK2 inhibitor, moving the Roivant company’s potential launch date from early 2027 to September 2026.
The Swiss major's immunology chief Angelika Jahreis tells Scrip of her high hopes for the potential pipeline-in-a-product.
The Japanese industrial material group expands its global presence with a strategic niche focus on immunology, organ transplantation, and severe infectious diseases.
The Flagship Pioneering company has completed the biggest initial public offering of 2026 so far, providing encouragement for more cash-hungry biotechs seeking a public listing.
Boehringer Ingelheim has strengthened its immunology research pipeline by licensing Sitryx’s preclinical oral small molecule program targeting immune-driven diseases.